Rosuvastatin reduces nonalcoholic fatty liver disease in patients with chronic hepatitis C treated with α-interferon and ribavirin: Rosuvastatin reduces NAFLD in HCV patients

BACKGROUND: Nonalcoholic fatty liver disease develops in patients with chronic hepatitis C. Interferon and ribavirin combination therapy is the standard treatment for chronic hepatitis C, but if present, NAFLD can reduce the virological response to anti-HCV therapies. OBJECTIVES: We determined wheth...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Malaguarnera, Michele, Vacante, Marco, Russo, Cristina, Gargante, Maria Pia, Giordano, Maria, Bertino, Gaetano, Neri, Sergio, Malaguarnera, Mariano, Galvano, Fabio, Volti, Giovanni Li
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Kowsar 2011
Aiheet:
Original Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC3206670/
https://ncbi.nlm.nih.gov/pubmed/22087124
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia